{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Glucan 1,3-beta-glucosidase : Questions médicales les plus fréquentes",
"headline": "Glucan 1,3-beta-glucosidase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Glucan 1,3-beta-glucosidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-18",
"dateModified": "2025-02-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Glucan 1,3-beta-glucosidase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cellulases",
"url": "https://questionsmedicales.fr/mesh/D044602",
"about": {
"@type": "MedicalCondition",
"name": "Cellulases",
"code": {
"@type": "MedicalCode",
"code": "D044602",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.277.450.420.200"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Glucan 1,3-beta-glucosidase",
"alternateName": "Glucan 1,3-beta-Glucosidase",
"code": {
"@type": "MedicalCode",
"code": "D043326",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Johannes Wagener",
"url": "https://questionsmedicales.fr/author/Johannes%20Wagener",
"affiliation": {
"@type": "Organization",
"name": "Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, Munich, Germany."
}
},
{
"@type": "Person",
"name": "Shigekazu Yano",
"url": "https://questionsmedicales.fr/author/Shigekazu%20Yano",
"affiliation": {
"@type": "Organization",
"name": "Graduate School of Sciences and Engineering, Yamagata University."
}
},
{
"@type": "Person",
"name": "Malgorzata Mikulska",
"url": "https://questionsmedicales.fr/author/Malgorzata%20Mikulska",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Malcolm Finkelman",
"url": "https://questionsmedicales.fr/author/Malcolm%20Finkelman",
"affiliation": {
"@type": "Organization",
"name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA."
}
},
{
"@type": "Person",
"name": "Yonglong Zhang",
"url": "https://questionsmedicales.fr/author/Yonglong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Speech/Language Impairment or Specific Learning Disability? Examining the Usage of Educational Categories.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36706457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_JSLHR-21-00636"
}
},
{
"@type": "ScholarlyArticle",
"name": "An investigation into the factor structure of the Health of the Nation Outcome Scales for People with Learning Disabilities.",
"datePublished": "2023-08-02",
"url": "https://questionsmedicales.fr/article/37530203",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jir.13070"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of COVID-19 on residents of long-term care facilities with learning disabilities and/or autism.",
"datePublished": "2023-04-26",
"url": "https://questionsmedicales.fr/article/37123814",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/irv.13139"
}
},
{
"@type": "ScholarlyArticle",
"name": "Maternal age at childbirth and the risk of attention-deficit/hyperactivity disorder and learning disability in offspring.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36817892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2023.923133"
}
},
{
"@type": "ScholarlyArticle",
"name": "Review and update of the Health of the Nation Outcome Scales for People with Learning Disabilities (HoNOS-LD).",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37198876",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/00207640231175773"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrolases",
"item": "https://questionsmedicales.fr/mesh/D006867"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosidases",
"item": "https://questionsmedicales.fr/mesh/D006026"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glucosidases",
"item": "https://questionsmedicales.fr/mesh/D005959"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cellulases",
"item": "https://questionsmedicales.fr/mesh/D044602"
},
{
"@type": "ListItem",
"position": 8,
"name": "Glucan 1,3-beta-glucosidase",
"item": "https://questionsmedicales.fr/mesh/D043326"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Glucan 1,3-beta-glucosidase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Glucan 1,3-beta-glucosidase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Glucan 1,3-beta-glucosidase",
"description": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?\nQuels tests sont utilisés pour mesurer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des marqueurs biologiques associés à cette enzyme ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Glucan 1,3-beta-glucosidase",
"description": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?\nLa déficience peut-elle causer des problèmes immunitaires ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Glucan 1,3-beta-glucosidase",
"description": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?\nY a-t-il des mesures préventives pour les symptômes ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation des patients est-elle importante ?\nLes conseils diététiques peuvent-ils prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Glucan 1,3-beta-glucosidase",
"description": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des thérapies alternatives recommandées ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nDes traitements expérimentaux sont-ils disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Glucan 1,3-beta-glucosidase",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle entraîner des infections fréquentes ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Glucan 1,3-beta-glucosidase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque de déficience ?\nLes facteurs environnementaux influencent-ils le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs socio-économiques influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests enzymatiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques spécifiques mesurent l'activité de la glucan 1,3-beta-glucosidase dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des douleurs abdominales ou des troubles digestifs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques associés à cette enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de glucanes dans le sang peuvent servir de marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations spécifiques dans le gène codant pour l'enzyme, confirmant le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleurs abdominales, et troubles de la digestion."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle causer des problèmes immunitaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une déficience peut affecter le système immunitaire, augmentant la susceptibilité aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir, bien que moins fréquents, comme des maux de tête."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais la déficience elle-même est généralement permanente."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déficience est généralement génétique, donc la prévention n'est pas possible."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications alimentaires et un suivi médical régulier peuvent aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les porteurs et informer sur les risques."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie et ses symptômes est cruciale pour une gestion efficace."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques peuvent-ils prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils diététiques appropriés peuvent aider à prévenir des complications digestives."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour soulager les symptômes digestifs et la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives, comme la phytothérapie, peuvent être envisagées, mais avec prudence."
}
},
{
"@type": "Question",
"name": "La diététique joue-t-elle un rôle dans le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation adaptée peut aider à réduire les symptômes et améliorer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Des traitements expérimentaux sont-ils disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des traitements expérimentaux, mais ils ne sont pas encore largement disponibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications digestives, immunitaires et neurologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle entraîner des infections fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une déficience en glucan 1,3-beta-glucosidase peut augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des troubles digestifs chroniques et des infections récurrentes."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une gestion proactive des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer l'apparition des symptômes, mais la déficience est généralement génétique."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas de preuves solides que les facteurs environnementaux influencent ce risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents médicaux de troubles digestifs peuvent augmenter la suspicion de déficience."
}
},
{
"@type": "Question",
"name": "Les facteurs socio-économiques influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs socio-économiques peuvent affecter l'accès aux soins, mais pas directement le risque génétique."
}
}
]
}
]
}
Developmental language disorder (DLD) is a lifelong condition that when impacting educational performance is identified and serviced through U.S. schools as outlined in the Individuals with Disabiliti...
We analyzed publicly available data released by the U.S. Department of Education from six school years between 2010 and 2020. We examined the use of S/LI and SLD categories across students of differen...
We present a trend in which younger students tend to be identified with the S/LI category, whereas older students tend to be identified with the SLD category. This trend is evident in all 6 years of d...
We discuss these findings in the context of research on language disorders to explain this trend. We highlight the potential damaging effects of using inconsistent terminology, including affecting the...
The Health of the Nation Outcome Scales for People with Learning Disabilities (HoNOS-LD) is one of the most used outcome measures in learning disability services in the United Kingdom. There is relati...
A data set of HoNOS-LD scales from 571 people with learning disabilities was randomly split into two halves. Exploratory Mokken analysis was applied to the first dataset, and confirmatory scale factor...
Two-factor and three-factor solutions were explored in the Mokken analysis, with the three-factor option having somewhat better characteristics. One-factor, three-factor and seven-factor solutions wer...
The HoNOS-LD is best conceptualised as consisting of three scales, accounting for 14 items that can be labelled as 'Cognitive and Physical Functioning', 'Behaviour and Mood Disturbances' and 'Function...
The COVID-19 pandemic has had disproportionate impact on vulnerable populations including those with learning disabilities. Assessing the incidence and risk of death in such settings can improve the p...
Surveillance records for COVID-19 infections in England from 02 February 2020 to 31 March 2022 were extracted. Data on property type, variant wave, vaccination, hospitalisation and death were derived ...
A total of 3501 individuals were identified as diagnosed with SARS-CoV-2 whilst living in 632 care home properties for learning disabilities and/or autism. Of the 3686 episodes of infection, 80.4% wer...
Care home residents with learning disabilities and/or autism have a greater risk of death from COVID-19. Optimising guidance to meet their needs is of great importance....
Studies have shown that young maternal age at childbirth can increase the risk of attention-deficit/hyperactivity disorder (ADHD) in offspring, but a study of the U.S. population has not been reported...
This study evaluated the association between young and advanced maternal age at childbirth and offspring risk of ADHD and LD in the U.S. population. Using data from 8,098 participants included in the ...
Among all participants, the offspring of subjects with a maternal age at childbirth of 18-24 years had an increased risk of ADHD (OR = 1.34, 95% CI: 1.01, 1.79) and LD (OR = 1.36, 95% CI: 1.06, 1.79) ...
These results provide epidemiological evidence showing that young and advanced maternal age at childbirth are associated with ADHD and LD risk....
The Health of the Nation Outcomes Scales for people with Learning Disabilities (HoNOS-LD) is an 18-item measure which provides a structured and standardized approach to rating various clinical and psy...
To revise and improve the HoNOS-LD's utility in contemporary intellectual disability (ID) services whilst retaining its original objectives and five-point severity ratings....
ID clinicians were invited to complete an online survey, rating each item on the existing measure for being fit for purpose, identifying issues and suggesting improvements based on their experience of...
A total of 75 individuals replied. Respondents had used HoNOS-LD for an average of 8.0 years (...
The changes outlined in this paper are based on the advisory group's expert consensus. These changes are intended to improve reliability and validity but now need empirical testing as well as review b...
Substantial progress has been made in defining children with nonverbal learning disability (NLD), but longitudinal studies are still lacking. To start filling this gap, we examined changes in general ...
Women with learning disabilities are less likely to breastfeed than other women. They may find it hard to understand or learn feeding techniques or know that they have infant feeding choices. This pop...
The use of restrictive practices has significant adverse effects on the individual, care providers and organisations. This review will describe how, why, for whom, and in what circumstances approaches...
Evidence from the literature will be synthesised using a realist review approach - an interpretative, theory-driven approach to understand how complex healthcare approaches work in reducing the use of...
Findings will be used to provide recommendations for practice and policymaking....
In accordance with the guidelines, this realist review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 4th December 2019 (CRD42019158432)....
This study used data from a national birth cohort study to investigate the duration of internet use at the age of 12 years among children diagnosed with attention-deficit/hyperactivity disorder (ADHD)...
The 5.5- and 12-year-old Taiwan Birth Cohort Study dataset was used (N = 17,694)....
More boys were diagnosed with LDs, IDs, ADHD and ASD; however, girls were at increased likelihood of PIU. ID and ASD diagnoses were not associated with increasing PIU likelihood. However, children who...
Dissociative absorption was found to be a mediating factor between childhood diagnosis and PIU and can be used as a screening indicator in prevention programs to reduce the duration and severity of PI...
Limited evidence exists concerning how a diagnosis of attention-deficit hyperactivity disorder and/or learning disabilities (ADHD/LD) modifies recovery and behavior following sport-related concussion ...